Table of Content

1 Key Insights

2 Executive Summary of Sarcopenia

3 SWOT Analysis for Sarcopenia

4 Sarcopenia Market Overview at a Glance
4.1 Market Share (%) Distribution of Sarcopenia in 2017
4.2 Market Share (%) Distribution of Sarcopenia in 2030

5 Disease Background and Overview
5.1 Introduction
5.2 Definition and classification
5.3 Causes
5.4 Risk factors
5.5 Pathophysiology
5.6 Biomarkers
5.7 Relevance to other disease states
5.8 Diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Prevalent Population of Sarcopenia in 7MM
6.3 Assumption and Rationale: 7MM

7 Country Wise-Epidemiology of Sarcopenia
7.1 The United States
7.1.1 Prevalent cases of Sarcopenia in the United States
7.1.2 Prevalence of Sarcopenia by Gender in the United States
7.2 Germany
7.2.1 Prevalent cases of Sarcopenia in Germany
7.2.2 Prevalence of Sarcopenia by Gender in Germany
7.3 France
7.3.1 Prevalent cases of Sarcopenia in France
7.3.2 Prevalence of Sarcopenia by Gender in France
7.4 Italy
7.4.1 Prevalent cases of Sarcopenia in Italy
7.4.2 Prevalence of Sarcopenia by Gender in Italy
7.5 Spain
7.5.1 Prevalent cases of Sarcopenia in Spain
7.5.2 Prevalence of Sarcopenia by Gender in Spain
7.6 The United Kingdom
7.6.1 Prevalent cases of Sarcopenia in the UK
7.6.2 Prevalence of Sarcopenia by Gender in the UK
7.7 Japan
7.7.1 Prevalent cases of Sarcopenia in Japan
7.7.2 Prevalence of Sarcopenia by Gender in Japan

8 Treatment and Management
8.1 Medical treatment directions
8.2 Guidelines
8.2.1 EWGSOP Guidelines
8.2.2 Asian Working Group for Sarcopenia (AWGS)
8.2.3 International Conference on Sarcopenia and Frailty Research (ICSFR)
8.3 Selective androgen receptor modulators (SARM)
8.4 Patient Journey

9 Unmet Needs

10 Appendix
10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight



List of Figures


Figure 1: SWOT Analysis
Figure 2: Criteria used to define Sarcopenia
Figure 3: Causes of Sarcopenia
Figure 4: The different pathways implicated in the pathogenesis of Sarcopenia
Figure 5: SARC-F Questionaire
Figure 6: Advantages and disadvantages of methods that can be used to measure muscle mass and strength
Figure 7: European Working Group of Sarcopenia in Older People
Figure 8: Total prevalent cases of Sarcopenia in 7MM (2017–2030)
Figure 9: Prevalent cases of Sarcopenia in the United States (2017–2030)
Figure 10: Prevalence of Sarcopenia by Gender in the United States(2017–2030)
Figure 11: Prevalent cases of Sarcopenia in Germany (2017–2030)
Figure 12: Prevalence of Sarcopenia by Gender in Germany (2017–2030)
Figure 13: Prevalent cases of Sarcopenia in France (2017–2030)
Figure 14: Prevalence of Sarcopenia by Gender in France (2017–2030)
Figure 15: Prevalent cases of Sarcopenia in Italy (2017–2030)
Figure 16: Prevalence of Sarcopenia by Gender in Italy (2017–2030)
Figure 17: Prevalent cases of Sarcopenia in Spain (2017–2030)
Figure 18: Prevalence of Sarcopenia by Gender in Spain (2017–2030)
Figure 19: Prevalent cases of Sarcopenia in the UK (2017–2030)
Figure 20: Prevalence of Sarcopenia by Gender in the UK (2017–2030)
Figure 21: Prevalent cases of Sarcopenia in Japan (2017–2030)
Figure 22: Prevalence of Sarcopenia by Gender in Japan (2017–2030)
Figure 23: Sarcopenia: EWGSOP2 algorithm
Figure 24: Sarcopenia: AWGS Guidelines
Figure 25: Mechanism of SARM Signaling
Figure 26: Patient Journey of Sarcopenia
Figure 27: Unmet Needs for Sarcopenia


List of Tables


Table 1: Summary of Sarcopenia Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total cases of Sarcopenia in 7MM (2017-2030)
Table 3: Prevalent cases of Sarcopenia in the United States (2017-2030)
Table 4: Prevalence of Sarcopenia by Gender in the United States (2017-2030)
Table 5: Prevalent cases of Sarcopenia in Germany (2017-2030)
Table 6: Prevalence of Sarcopenia by Gender in Germany (2017-2030)
Table 7: Prevalent cases of Sarcopenia in France (2017-2030)
Table 8: Prevalence of Sarcopenia by Gender in France (2017-2030)
Table 9: Prevalent cases of Sarcopenia in Italy (2017-2030)
Table 10: Prevalence of Sarcopenia by Gender in Italy (2017-2030)
Table 11: Prevalent cases of Sarcopenia in Spain (2017-2030)
Table 12: Prevalence of Sarcopenia by Gender in Spain (2017-2030)
Table 13: Prevalent cases of Sarcopenia in the UK (2017-2030)
Table 14: Prevalence of Sarcopenia by Gender in the UK (2017-2030)
Table 15: Prevalent cases of Sarcopenia in Japan (2017-2030)
Table 16: Prevalence of Sarcopenia by Gender in Japan (2017-2030)